加载中
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.
前收盘价
US$8.34
−US$0.32 · -3.70%
盘前
US$8.50
+US$0.16 · +1.92%
10月12日 7:01 ET
盘中时间采用ET。市场数据可能有所延迟。
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.
日内区间
当前US$8.34
52周区间
当前US$8.34
盘中时间采用ET。市场数据可能有所延迟。
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.
日内区间
当前US$8.34
52周区间
当前US$8.34
营业利润
净利润
| 项目（CHF） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | 68.6万 CHF | — | — | — |
| 销货成本 | — | 5208.3万 CHF | — | — | — |
| 毛利 | — | −5139.7万 CHF | — | — | — |
| 研究与开发 | 5451.86万 CHF | 5208.3万 CHF | 2924.7万 CHF | 2222.4万 CHF | 956.8万 CHF |
| 销售、一般及管理费用 | 2462.67万 CHF | 2180.7万 CHF | 1472.4万 CHF | 674.3万 CHF | 409.7万 CHF |
| 营业费用 | 7914.54万 CHF | 2180.7万 CHF | 8071.4万 CHF | 3237.6万 CHF | 1323.2万 CHF |
| 利息收入 | 169.04万 CHF | 216.8万 CHF | 159.02万 CHF | 12.6万 CHF | 2.1万 CHF |
| 利息支出 | 79.56万 CHF | 63.9万 CHF | 146.33万 CHF | 644.2万 CHF | 512万 CHF |
| 折旧和摊销 | 54.6万 CHF | 40.6万 CHF | 28.7万 CHF | 29.9万 CHF | 23.5万 CHF |
| 营业利润 | −7914.54万 CHF | −7320.4万 CHF | −8071.4万 CHF | −3237.6万 CHF | −1323.2万 CHF |
| 净利润 | −9450.82万 CHF | −8577.7万 CHF | −8880.2万 CHF | −3869.8万 CHF | −1855.2万 CHF |
公司数据更新于 2026年10月12日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
ALPS Medical Breakthroughs ETFSBIO65.25万0.34%1.91亿 USD0.50%US$55.04+2.03%
Virtus Biotech Clinical Trials ETFBBC24.78万0.60%4099.65万 USD0.65%US$44.1456+2.08%
State Street SPDR S&P International Small Cap ETFGWX24.64万0.03%9.08亿 USD0.40%US$45.56+0.93%
Fidelity Nasdaq Composite Index ETFONEQ21.78万—109.4亿 USD0.21%US$107.81+0.63%
GlacierShares Nasdaq Iceland ETFGLCR5.93万4.15%142.77万 USD0.95%US$23.69+0.77%ALPS Medical Breakthroughs ETFSBIOVirtus Biotech Clinical Trials ETFBBCState Street SPDR S&P International Small Cap ETFGWXFidelity Nasdaq Composite Index ETFONEQGlacierShares Nasdaq Iceland ETFGLCRAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
